The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury

Pang, Juan; Feng, Jia Nuo; Ling, Wenhua; Jin, Tianru

doi:10.1016/j.apsb.2022.06.003

Cited by 11 publications

(4 citation statements)

References 187 publications

(276 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This success could be attributed to an anti-inflammatory secondary feature of GLP-1RA’s. The anti-inflammatory capabilities of GLP-1RA’s were first described back in 2007 by Viswanathan et al as “non-metabolic actions” of Exenatide, and further research throughout the years have shown GLP-1RA’s to attenuate circulating hs-CRP levels, regulate and lower systolic blood pressure, and reduce inflammatory markers in vivo such as TNF- α , IL-1β, and IL-6 ( Viswanathan et al, 2007 ) ( Pang et al, 2022 ). They have also been shown to dysregulate key signalling pathways of inflammation, such as NF-κB, MAPK, PKA/STAT3, and PI3K/Akt ( Chen et al, 2022 ).…”

Section: Current Treatmentsmentioning

confidence: 99%

Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies

Millar

Gaetano²

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Atherosclerosis is a progressive, multifactorial inflammatory, and dyslipidaemic disease, responsible for the majority of cardiovascular diseases globally. The chronic inflammation is the main driver of the initiation and progression of such disease, as a result of an imbalanced lipid metabolism and an ineffective immune response to attenuate the inflammatory component. The importance of inflammation resolution is being increasingly recognised in atherosclerosis and cardiovascular disease. It has a complex mechanism consisting of multiple stages, including restoring an effective removal of apoptotic bodies (efferocytosis) and their degradation (effero-metabolism), a macrophage phenotype switching towards resolving phenotypes, and the promotion of tissue healing and regeneration. The low-grade inflammation associated with atherosclerosis development is a driving force in disease exacerbation, and hence inflammation resolution is a key area of research. In this review, we explore the complex disease pathogenesis and its many contributing factors to gain a greater understanding of the disease and identify the current and potential therapeutic targets. First-line treatments and their efficacy will also be discussed in detail, to highlight the emerging field of resolution pharmacology. Despite the great efforts made by current gold-standard treatments, such as lipid-lowering and glucose-lowering drugs, they remain ineffective at tackling residual inflammatory risk and residual cholesterol risk. Resolution pharmacology represents a new era of atherosclerosis therapy, as endogenous ligands associated with inflammation resolution are exploited for their pharmacological benefits in a more potent and longer-acting manner. Novel FPR2-agonists, such as synthetic lipoxin analogues, provide an exciting new approach to enhance the pro-resolving response of the immune system and subsequently end the pro-inflammatory response to allow for an anti-inflammatory and pro-resolving environment for tissue healing, regeneration, and return to homeostasis.

show abstract

Section: Current Treatmentsmentioning

confidence: 99%

Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies

Millar

Gaetano²

2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In human studies, patients with T2D have been reported to have increased inflammation and oxidative stress, which leads to insulin resistance [ 119 , 120 ]. Exenatide’s anti-inflammatory properties have been well studied in T2D patients [ 121 ]. Viswanathan et al, revealed that exenatide successfully manages T2D in individuals with obesity who are insulin-dependent, resulting in lowered C-reactive protein (CRP) and other metabolic parameters, including HbAlc, systolic blood pressure, and TG [ 122 ].…”

Section: Glp-1 and Glp-2 As Regulators Of Intestine Integrity And Inf...mentioning

confidence: 99%

GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk

Abdalqadir

Adeli

2022

Microorganisms

View full text Add to dashboard Cite

The intestine represents the body’s largest interface between internal organs and external environments except for its nutrient and fluid absorption functions. It has the ability to sense numerous endogenous and exogenous signals from both apical and basolateral surfaces and respond through endocrine and neuronal signaling to maintain metabolic homeostasis and energy expenditure. The intestine also harbours the largest population of microbes that interact with the host to maintain human health and diseases. Furthermore, the gut is known as the largest endocrine gland, secreting over 100 peptides and other molecules that act as signaling molecules to regulate human nutrition and physiology. Among these gut-derived hormones, glucagon-like peptide 1 (GLP-1) and -2 have received the most attention due to their critical role in intestinal function and food absorption as well as their application as key drug targets. In this review, we highlight the current state of the literature that has brought into light the importance of GLP-1 and GLP-2 in orchestrating intestine–microbiota–immune system crosstalk to maintain intestinal barrier integrity, inflammation, and metabolic homeostasis.

show abstract

“…[ 13,14 ] Notably, GLP‐1 not only suppresses appetite but also promotes fatty acid oxidation and thermogenesis, thereby increasing energy expenditure. [ 15,16 ] Therefore, GLP‐1 represents a potential target for preventing and intervening in obesity development. [ 17,18 ] However, it is essential to acknowledge that GLP‐1 agonist therapy is the primary approach for weight reduction, but it often comes with adverse effects, such as gastrointestinal symptoms.…”

Section: Introductionmentioning

confidence: 99%

Profiles of Intestinal Flora in Breastfed Obese Children and Selecting Functional Strains Against Obesity

Liang,

Niu,

Lyu

et al. 2024

Molecular Nutrition Food Res

View full text Add to dashboard Cite

ScopeBreast milk has the potential to prevent childhood obesity by providing probiotics, but there are still instances of obesity in breastfed children.Methods and ResultsThis study investigates the difference in intestinal flora structure between breastfed children with obesity (OB‐BF) and normal‐weight breastfed children (N‐BF). Building upon this foundation, it employs both cell and mouse models to identify an antiobesity strain within the fecal matter of N‐BF children and explore its underlying mechanisms. The results reveal a reduction in lactobacillus levels within the intestinal flora of OB‐BF children compared to N‐BF children. Consequently, Lactobacillus plantarum H‐72 (H‐72) is identified as a promising candidate due to its capacity to stimulate glucagon‐like peptide‐1 (GLP‐1) secretion in enteroendocrine cells (ECCs). In vivo, H‐72 effectively increases serum GLP‐1 concentration, reduces food intake, regulates the expression of genes related to energy metabolism (SCD‐1, FAS, UCP‐1, and UCP‐3), and regulates gut microbiota structure in mice. Moreover, the lipoteichoic acid of H‐72 activates toll‐like receptor 4 to enhanced GLP‐1 secretion in STC‐1 cells.ConclusionsL. plantarum H‐72 is screened out for its potential antiobesity effect, which presents a potential and promising avenue for future interventions aimed at preventing pediatric obesity in breastfed children.

show abstract

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury

Cited by 11 publications

References 187 publications

Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies

Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies

GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk

Profiles of Intestinal Flora in Breastfed Obese Children and Selecting Functional Strains Against Obesity

Contact Info

Product

Resources

About